[Preliminary study on postremission therapy courses in acute myeloid leukemia]

Area of Science:

• Hematology
• Oncology
• Clinical Research

Context:

• Acute myeloid leukemia (AML) is a complex hematologic malignancy.
• Optimizing post-remission therapy is crucial for improving patient survival and reducing relapse rates.
• Current treatment protocols vary, necessitating research into the ideal number of therapy courses.

Purpose:

• To determine the optimal number of post-remission therapy courses for adult patients with acute myeloid leukemia (AML).
• To evaluate the impact of varying post-remission therapy durations on disease-free survival (DFS) and overall survival (OS) in AML patients.

Summary:

• This study analyzed data from 191 de novo AML patients, assessing outcomes based on induction chemotherapy and post-remission therapy courses.
• Patients receiving six or more courses of post-remission therapy demonstrated significantly improved median DFS (35.3 months) and 3-year survival (43.2%) compared to those receiving fewer than six courses.
• Receiving eight or more courses further enhanced outcomes, with a median DFS of 48.8 months and a 3-year survival rate of 57.9%.

Impact:

• Findings suggest that a minimum of six post-remission therapy courses is beneficial for AML patients.
• Eight or more courses of post-remission therapy may represent a more effective strategy for improving long-term survival in AML.
• This research provides evidence-based recommendations for refining post-remission treatment protocols in AML management.